Table 3 The demographics and baseline characteristics of selenium insufficiency patient with and without selenium administration.
From: Impact of selenium status and supplementation on outcomes in critically ill patients
Total sample n = 40 | Supplement Se (+) n = 23 | Supplement Se (−) n = 17 | P value | |
|---|---|---|---|---|
Age | 68.0 ± 15.6 | 71.6 ± 15.7 | 63.1 ± 14.5 | 0.071 |
Age > 65 | 26(66%) | 18(78.3%) | 8(47.1%) | 0.041 |
Male | 25(62.5%) | 14(60.9%) | 11(64.7%) | 0.804 |
Selenium level | 55.6 ± 12.5 | 53.9 ± 12.8 | 57.9 ± 12.0 | 0.404 |
Comorbidity | ||||
Diabetes mellitus | 17(42.5%) | 11(47.8%) | 6(35.3%) | 0.428 |
Hypertension | 25(62.5%) | 15(65.2%) | 10(58.8%) | 0.680 |
Coronary artery disease | 6(15%) | 2(8.7%) | 4(23.5%) | 0.373 |
Chronic obstructive pulmonary disease | 6(15%) | 2(8.7%) | 4(23.5%) | 0.373 |
Stroke | 2(5%) | 2(8.7%) | 0(0%) | 0.499 |
Liver cirrhosis | 2(5%) | 1(4.3%) | 1(5.9%) | 1.000 |
End-stage renal disease | 4(10%) | 1(4.3%) | 3(17.6%) | 0.294 |
Autoimmune disease | 1(2.5%) | 0(0%) | 1(5.9%) | 0.425 |
Alcohol | 3(7.5%) | 1(5.9%) | 2(11.8%) | 0.565 |
Cancer | 15(37.5%) | 9(39.1%) | 6(35.3%) | 0.804 |
Total comorbidity ≥ 2 | 25(62.5%) | 13(56.5%) | 12(70.6%) | 0.364 |
